Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. Articles
  3. fatty liver disease
Show results for
Products
Services
Applications

Companies

News
Articles
Videos

Refine by
Date

  • This Year
  • Older

Fatty Liver Disease Articles & Analysis

17 articles found

Preclinical Models of Non-Alcoholic Fatty Liver Disease

Preclinical Models of Non-Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) has emerged as a significant public health concern, associated with obesity, insulin resistance, and a spectrum of metabolic disorders. ...

ByCreative Bioarray


Ox Bile Extract Powder: A Comprehensive Review of Its Physiological Functions and Therapeutic Potential

Ox Bile Extract Powder: A Comprehensive Review of Its Physiological Functions and Therapeutic Potential

Individuals with reduced bile production or impaired bile flow, such as those with gallbladder disease or liver dysfunction, may benefit from supplementation with ox bile extract powder to improve fat digestion and absorption, potentially alleviating symptoms related to malabsorption and steatorrhea. Additionally, by promoting the excretion of cholesterol, ox ...

ByCreative Enzymes


Regulation of Lipid Metabolism in the Intestinal Flora

Regulation of Lipid Metabolism in the Intestinal Flora

Dysbiosis of the intestinal flora is associated with a variety of human metabolic diseases, such as obesity, diabetes mellitus, and nonalcoholic fatty liver disease. ...

ByCreative Proteomics


Exploring the Intricate Link Between Bile Acids and Disease

Exploring the Intricate Link Between Bile Acids and Disease

Dysbiosis, an imbalance in gut microbial communities, has been linked to altered bile acid metabolism and, consequently, to diseases like non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes. ...

ByCreative Proteomics


Huateng Pharma Supplies Canagliflozin Intermediates With Commercial Scale Production

Huateng Pharma Supplies Canagliflozin Intermediates With Commercial Scale Production

However, compared with the classic uric acid-lowering drugs, its effect is relatively weak, so it is more promising to be used in patients with asymptomatic hyperuricemia or diabetes complicated with hyperuricemia. 6. Liver protection SGLT2 inhibitors can protect the liver by altering the glucose-fatty acid cycle, increasing the utilization and ...

ByHunan Huateng Pharmaceutical Co. Ltd.


In Silico Development of Combinatorial Therapeutic Approaches Targeting Key Signaling Pathways in Metabolic Syndrome

In Silico Development of Combinatorial Therapeutic Approaches Targeting Key Signaling Pathways in Metabolic Syndrome

Introduction Metabolic syndrome (MetS) is a group of clinical conditions manifested as abdominal obesity, hyperglycemia, hypertension, dyslipidemia, and chronic inflammation, concurrently leading to a marked increase in the risk of heart disease, diabetes, and stroke, or all three (1, 2). Currently, MetS is a growing health concern due to its increasing prevalence globally (3). ...

ByVeriSIM Life


MRE plus FIB-4 (MEFIB) versus FAST in detection of candidates for pharmacological treatment of NASH-

MRE plus FIB-4 (MEFIB) versus FAST in detection of candidates for pharmacological treatment of NASH-

Abstract Background and aim: Nonalcoholic fatty liver disease (NAFLD) patients with significant hepatic fibrosis (stage ≥ 2) are at increased risk of liver-related morbidity and are candidates for pharmacologic therapies. In this study, we compared the diagnostic accuracy of MEFIB (the combination of magnetic resonance ...

ByResoundant, Inc.


MRE associated with increased risk of cardiovascular disease in patients with NAFLD - Case study

MRE associated with increased risk of cardiovascular disease in patients with NAFLD - Case study

A new study was published in March of 2021 demonstrating that elevated liver stiffness, as measured by magnetic resonance elastography (MRE), is associated with higher rates of cardiovascular disease in patients with non-alcoholic fatty liver disease (NAFLD). As clinical researchers, regulators and pharmaceutical ...

ByResoundant, Inc.


Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD

Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD

Nonalcoholic fatty liver disease (NAFLD) is associated with obesity but also found in non-obese individuals. ...

ByKoBioLabs


How the Emerging NAFLD-NASH Crisis Underscores the Urgent Need for Better Diagnostics

How the Emerging NAFLD-NASH Crisis Underscores the Urgent Need for Better Diagnostics

With NAFLD and NASH now affecting well over 1 billion people globally, the world needs better diagnostics to accurately detect liver disease in an affordable, easy-touse and safe manner. Abstract Non-Alcoholic Fatty Liver Disease (NAFLD) and its inflammatory stage, Non-Alcoholic SteatoHepatitis (NASH), are now a ...

ByENDRA Life Sciences Inc.


Estimation of stones in gallbladder with FT-IR | JBES Journals

Estimation of stones in gallbladder with FT-IR | JBES Journals

The gallbladder is a slender pear- shaped organ in a right superior belly (Le Bail et al., 1992), the region below the liver which links chest to hips. Gallstones can vary between a1cm and 13cm in size. ...

ByInternational Network for Natural Sciences (INNSPUB)


Roseburia spp. Abundance Associates with Alcohol Consumption in Humans and Its Administration Ameliorates Alcoholic Fatty Liver in Mice

Roseburia spp. Abundance Associates with Alcohol Consumption in Humans and Its Administration Ameliorates Alcoholic Fatty Liver in Mice

Highlights The depletion of Roseburia is associated with alcohol consumption in human cohorts R. intestinalis ameliorates the experimental ALD in mice regardless of viability Flagellin from R. intestinalis protects on ethanol-disrupted gut barrier functions The ethanol-induced gut microbiota dysbiosis is restored by R. intestinalis Summary Although a link between the gut microbiota ...

ByKoBioLabs


Nonalcoholic Fatty Liver and How Fucoxanthin Might Help

Nonalcoholic Fatty Liver and How Fucoxanthin Might Help

Many may not have heard of nonalcoholic fatty liver (NAFL) yet it is a very common condition. If NAFL is not addressed, it can progress to a serious condition known as Nonalcoholic fatty liver disease (NAFLD) Non-alcoholic fatty liver is the buildup of extra fat in ...

ByAlgatech


Cells isolated from donors with nonalcoholic fatty liver disease exhibit disease phenotypes in 3D bioprinted human liver tissue

Cells isolated from donors with nonalcoholic fatty liver disease exhibit disease phenotypes in 3D bioprinted human liver tissue

Publication Summary: The identification of targets and biomarkers and development of therapeutics for nonalcoholic fatty liver disease (NAFLD) may be accelerated by the use of well-characterized primary cell and tissue reagents, as well as improved in vitro human cell-based disease models, including three-dimensional (3D) ...

ByOrganovo Holdings Inc.


Degradation of splicing factor SRSF3 contributes to progressive liver disease

Degradation of splicing factor SRSF3 contributes to progressive liver disease

As a consequence, genetic deletion of SRSF3 in hepatocytes caused progressive liver disease and ultimately led to hepatocellular carcinoma. Here we show that SRSF3 is decreased in human liver samples with nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), or cirrhosis ...

ByJohnson Controls, Inc.


Modeling NAFLD using 3D bioprinted human liver tissue

Modeling NAFLD using 3D bioprinted human liver tissue

Publication Summary: Nonalcoholic fatty liver disease (NAFLD) is a chronic condition that originates as lipid accumulation within hepatocytes (steatosis) and progresses into nonalcoholic steatohepatitis (NASH), characterized by lipid accumulation, inflammation, oxidative stress, and fibrosis. NAFLD is now recognized as the most common cause of ...

ByOrganovo Holdings Inc.


Modeling NAFLD using 3D bioprinted human liver tissue

Modeling NAFLD using 3D bioprinted human liver tissue

Publication Summary: Nonalcoholic fatty liver disease (NAFLD) is a chronic condition that originates as lipid accumulation within hepatocytes (steatosis) and progresses into nonalcoholic steatohepatitis (NASH), characterized by lipid accumulation, inflammation, oxidative stress, and fibrosis. NAFLD is now recognized as the most common cause of ...

ByOrganovo Holdings Inc.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT